Skip to content

NIRAF-Guided Parathyroid Identification During Thyroidectomy

Near-Infrared Autofluorescence-Guided Parathyroid Identification During Thyroidectomy

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07617584
Enrollment
280
Registered
2026-06-01
Start date
2026-06-01
Completion date
2029-12-01
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Goiter, Nodular, Hypocalcemia, Hypoparathyroidism, Thyroid Diseases, Thyroidectomy, Thyroid Nodule

Keywords

Near-Infrared Autofluorescence, NIRAF, Parathyroid Identification, Parathyroid Preservation, Thyroidectomy, Completion Thyroidectomy, Total Thyroidectomy, Postoperative Hypocalcemia, Intact Parathyroid Hormone, iPTH, Rescue Autotransplantation, Wearable Imaging, Post-thyroidectomy hypocalcemia

Brief summary

This is a single-site, two-component prospective study evaluating whether near-infrared autofluorescence (NIRAF) imaging can improve intraoperative identification of parathyroid glands during thyroidectomy and reduce postoperative hypocalcemia. The investigational platform is a modified wearable stereoscopic goggle system configured for label-free NIRAF imaging. Parathyroid tissue is excited with near-infrared light at approximately 780 nm and emits autofluorescence centered near 800 nm. No injected dye or external contrast agent is used. The goggles are used only during a brief mapping interval after thyroid exposure and for ex vivo interrogation of the resected thyroid specimen. Component A is a prospective observational run-in validation cohort of 30 adults undergoing thyroidectomy of any extent. NIRAF-positive foci on the intact thyroidectomy specimen are suture-marked and correlated with targeted pathology. Component B is a randomized clinical study of 250 adults undergoing total or completion thyroidectomy. Participants are randomized 1:1 to standard surgery or standard surgery plus brief in vivo NIRAF mapping, ex vivo specimen interrogation, and rescue autotransplantation when indicated. The primary outcome for Component B is transient biochemical hypocalcemia on postoperative day 1, defined using albumin-corrected serum calcium.

Detailed description

Near-infrared autofluorescence (NIRAF) imaging is being evaluated as a structured adjunct to standard thyroidectomy for localization and preservation of parathyroid tissue. Parathyroid tissue emits intrinsic near-infrared autofluorescence without administration of dye or other contrast agent. The study imaging platform is a modified head-mounted stereoscopic goggle system that provides near-infrared excitation at approximately 780 nm and detects autofluorescence centered near 800 nm. Imaging is non-contact and is performed only during a brief prespecified in vivo mapping interval and ex vivo back-table specimen interrogation. The study includes a run-in validation component followed by a randomized interventional component. In the run-in component, ex vivo imaging of thyroidectomy specimens is used to standardize imaging conditions, documentation, suture marking, specimen mapping, and pathology correlation for NIRAF-positive foci. In the randomized component, participants undergoing total or completion thyroidectomy are randomized to standard surgery or standard surgery plus adjunct NIRAF mapping. In the intervention arm, the surgeon records parathyroid glands identified under white light before mapping, then uses NIRAF information as an adjunct to standard anatomy and surgical judgment. After thyroid removal, ex vivo specimen imaging may be used to identify NIRAF-bright foci that could represent inadvertently excised parathyroid tissue. Rescue autotransplantation may be performed only when clinically appropriate and oncologically safe. NIRAF findings are intended to supplement, not replace, standard operative assessment, surgical anatomy, pathology review, or oncologic decision-making.

Interventions

DEVICEWearable Near-Infrared Autofluorescence Imaging System

A modified Meta head-mounted stereoscopic goggle system configured for label-free near-infrared autofluorescence imaging. The system delivers near-infrared excitation at approximately 780 nm and detects parathyroid autofluorescence centered near 800 nm. No injected dye or external contrast agent is administered. The device is used briefly after thyroid exposure for in vivo mapping and after thyroid resection for ex vivo specimen interrogation.

Sponsors

Ss. Cyril and Methodius University of Skopje
Lead SponsorOTHER
University of Illinois at Urbana-Champaign
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Masking description

The study is open label. Blinding of the operating surgeon is not feasible because the intervention involves intraoperative use of the NIRAF imaging device. Laboratory values and pathology findings are objective outcomes and will be analyzed using prespecified definitions.

Intervention model description

This study includes two linked components. Component A is a prospective observational run-in validation cohort of 30 participants undergoing thyroidectomy of any extent. Component B is a prospective randomized parallel-group study of 250 participants undergoing total or completion thyroidectomy. Component B participants are randomized 1:1 to standard surgery or standard surgery plus brief in vivo NIRAF mapping, ex vivo specimen interrogation, and rescue autotransplantation when indicated.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older. * For Component A: planned thyroidectomy of any extent with an intact specimen available for ex vivo evaluation. * For Component B: planned total or completion thyroidectomy. * Ability to provide written informed consent before surgery. * Willingness to comply with routine postoperative laboratory testing and follow-up when feasible.

Exclusion criteria

* Known pre-existing hypoparathyroidism or prior parathyroid surgery. * Severe chronic kidney disease or end-stage renal disease expected to substantially confound calcium and parathyroid hormone interpretation, as defined by the site investigator. * Pregnancy. * For Component B only: gross nodal disease or a surgical plan requiring extensive nodal packet dissection in the current study phase. * Any condition that, in the judgment of the investigator, would make participation unsafe or compromise protocol adherence.

Design outcomes

Primary

MeasureTime frameDescription
Postoperative Day 1 Biochemical HypocalcemiaPostoperative Day 1Proportion of randomized Component B participants with transient biochemical hypocalcemia on postoperative day 1, defined as albumin-corrected total serum calcium below the lower limit of the institutional clinical laboratory reference range in use at study activation.

Secondary

MeasureTime frameDescription
Early Intact Parathyroid Hormone2 to 4 hours postoperatively, with optional assessment on Postoperative Day 1Early intact parathyroid hormone concentration used as an acute physiologic correlate of in situ parathyroid gland function.
Mapping YieldIntraoperativeNumber of parathyroid-consistent NIRAF sites identified during the intraoperative mapping interval.
Additional NIRAF Sites Beyond White-Light AssessmentIntraoperativeNumber of NIRAF sites identified that were not included in the surgeon's pre-mapping white-light declaration.
Mapping EfficiencyIntraoperativeTime to first parathyroid identification with NIRAF imaging and total duration of the intraoperative mapping interval.
Incidental Parathyroid Tissue in the Thyroidectomy SpecimenPostoperative pathology review (up to 30 days postoperatively)Presence and number of histologically confirmed parathyroid glands or parathyroid tissue fragments identified in the thyroidectomy specimen, including size when feasible. The number of confirmed parathyroid glands or tissue foci may be summarized categorically as 0, 1, 2, 3, or 4 when applicable.
Rescue Autotransplantation EventsIntraoperativeWhether rescue autotransplantation was performed, including tissue source, implant site, and number of fragments implanted.
Longer-Term Albumin-Corrected Serum CalciumPostoperative week 8 and postoperative month 6Albumin-corrected total serum calcium concentration measured at postoperative follow-up.
Longer-Term Intact Parathyroid HormonePostoperative week 8 and postoperative month 6Serum intact parathyroid hormone concentration measured at postoperative follow-up.
Calcium or Calcitriol Supplementation at Follow-UpPostoperative week 8 and postoperative month 6Use of oral calcium and/or calcitriol supplementation at postoperative follow-up.

Countries

North Macedonia

Contacts

CONTACTMagdalena Bogdanovska Todorovska, MD, PhD
magdalena.todorovska@medf.ukim.edu.mk+389-70960221
CONTACTBorislav Kondov, MD, PhD
borislav.kondov@medf.ukim.edu.mk+389.72539003
PRINCIPAL_INVESTIGATORMagdalena Bogdanovska Todorovska, MD, PhD

Ss. Cyril and Methodius University of Skopje

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 2, 2026